

BETABIOPHARM PRIVATE LIMITED

03RD ANNUAL REPORT 2024-25

Board of Directors

Sonu Meena (Director w.e.f. 07/10/2022)

Kunal Shinde (Additional Director w.e.f. 10/07/2025)

Auditors

M/s Mittal Agarwal & Company Chartered Accountants, Mumbai

Registered Office

FF-127, Windsor Plaza Nr. Express Hotel, Alkapuri, Vadodara, Gujarat, India, 390007

CONTENTS
Notice
Board's Report
Auditor's Report
Balance Sheet
Profit & Loss Account
Notes to Account

BETABIOPHARM PRIVATE LIMITED

Registered Office: FF-127, Windsor Plaza Nr. Express Hotel, Alkapuri, Vadodara,
Gujarat, India, 390007

CIN: U51909GJ2022PTC135997

Email: betabiopharm@gmail.com

Contact No.- 9754731000

BOARD'S REPORT

Dear Shareholders,

Your directors have pleasure in presenting the 03rd Annual Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2025.

1. FINANCIAL SUMMARY/ STATE OF COMPANYS AFFAIRS / REVIEW OF OPERATIONS:

During the year under report financial results are as under:

INR (Amount in Lakhs)

Particulars	2024-25	2023-24
Revenue from Operation	3405.73	1288.34
Other Income	0.00	0.01
Total Income	3405.73	1288.35
Less:- Total Expenditure	3053.06	1286.55
Profit / (Loss) Before Tax	352.68	1.80
Tax Expenses:		
Current Tax	88.77	0.00
Less: MAT Credit Entitlement	0.00	0.00
Earlier Year Tax Adjustment	0.00	0.00
Deferred Tax	0.00	0.00
Total Tax Expenses	0.00	0.00
Profit / (Loss) for the year	263.91	1.80

2. PERFORMANCE AND THE STATE OF AFFAIRS OF THE COMPANY:

During the year under review, your Company has earned profit of Rs. 26391000 as compared to profit of Rs. 180000 in the previous year.

3. EVENT SUBSEQUENT TO THE DATE OF FINANCIAL STATEMENTS:

There are no material changes and commitments affecting the financial position of the Company between 31st March, 2025 till the date of Board's report.

4. **CHANGE IN THE NATURE OF THE BUSINESS, IF ANY:**

During the year, Company has not changed its nature of business.

5. **DIVIDEND:**

Due to long term requirements of fund for future projects of the Company, Your Directors have not recommended any dividend for the year ended 31st March 2025.

6. **RESERVES:**

All the Profit and loss for the year which is able to transfer in the Reserves and Surplus of the Company, the Board proposes to transfer the profit arises during the year in to the surplus account of the Company.

7. **NUMBER OF MEETINGS OF BOARD:**

The Board of Directors met five (5) times during this year. Details are given as follows:

S. No.	Date of meeting (DD/MM/YYYY)	Total Number of directors as on the date of meeting	Attendance	
			Number of directors attended	% of attendance
1.	08-04-2024	2	2	100
2.	20-05-2024	2	2	100
3.	02-09-2024	2	2	100
4.	30-12-2024	2	2	100
5.	14-03-2025	2	2	100

8. **SHARE CAPITAL**

During the year, the Company has not altered its Authorized Share Capital of Rs. 11,00,000/- (Rupees Eleven Lacs Only) and there has been no change in Paid up Share Capital of the Company and remain same i.e. Rs. 11,00,000/- (Rupees Eleven Lacs Only).

9. **DIRECTORS AND KEY MANAGERIAL PERSON:**

During the year under review the constitution of board during the year is as follows:-

Sr. No.	Name	Designation	Date of appointment	Date of cessation & Mode of Cessation
1.	Jasmina Prem Aildasani	Director	07/10/2022	10/07/2025
2.	Sonu Meena	Director	07/10/2022	----
3.	Kunal Shinde	Additional Director	10/07/2025	----

After the end of the financial year but before the date of Board report Mr. Kunal Shinde was Appointed as Additional Director of the company w.e.f. 10th July, 2025 and Mr.

Kunal Shinde have offered to regularize as Director in ensuing Annual General Meeting of the Company.

Further, Mrs. Jasmina Prem Aildasani has resigned w.e.f. 10th July, 2025 from the post of Directorship of the Company and the entire Board have appreciated for their contribution given for upliftment of the Company.

10. DIRECTORS' RESPONSIBILITY STATEMENT:

Your Director made the following statement in the term of in pursuance of section 134 (5) of the Companies Act, 2013 to the best of their knowledge and belief and according to the information and explanation obtained by them;

- i) that in the preparation of Annual Accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- ii) that directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the Profit of the Company for that period;
- iii) that directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv) That directors had prepared the annual Accounts on a going concern basis;
- v) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

11. DECLARATION BY INDEPENDENT DIRECTORS

The provisions of Section 149 pertaining to the appointment of Independent Directors do not apply to the Company hence the Company need not to require getting declarations from Independent Directors as prescribed under provisions of section 149 the Companies Act, 2013.

12. INFORMATION ABOUT THE FINANCIAL PERFORMANCE/ FINANCIAL POSITION OF THE SUBSIDIARIES/ASSOCIATES/JOINT VENTURE

There was no subsidiary, associate or joint venture of the Company during the year under review.

13. COMPANIES WHICH HAVE BECOME/CEASED TO BE SUBSIDIARIES, JVS OR ASSOCIATE COMPANIES DURING THE YEAR

There was no subsidiary, associate or joint venture of the Company during the year under review.

14. ANNUAL RETURN / WEB ADDRESS:

Every Company shall place a copy of the annual return on the website of the Company in pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules 2014, since The Company is not having its web address consequently this requirement is not applicable on the Company.

15. **AUDITORS:**

M/s Mittal Agarwal & Company Chartered Accountants, Mumbai (Firm Registration No. 0131025W) Statutory Auditor of the Company appointed as the Statutory Auditors for the period of 5 years starting from 01.04.2024 to 31.03.2029 in the Annual General Meeting held in the year 2024 on such remuneration as may be decided by the Board of Directors as per section 139 of the Companies Act, 2013.

16. **AUDITORS' REPORT:**

The Auditor's Report read with the relevant notes as given in the Notes to Annual Accounts for the year ended March 31, 2025 are self-explanatory, further There is no qualifying remark in the Auditor's Report and hence does not require any clarification in the Director's Report under Section 134(3) of the Companies Act, 2013.

17. **DETAILS OF FRAUD REPORTED BY AUDITORS**

There is no fraud happened in the Company during the year thus the statutory auditor has not commented in his report under the section 143 (12) of the Companies Act, 2013.

18. **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO:**

During the year, as per the provisions of section 134 of the Companies Act, 2013, the information pertaining to Conservation of Energy, Technology absorption & foreign exchange earning & outgo are enclosed in **(Annexure I)**.

19. **DEPOSIT:**

The Company has neither accepted nor renewed any deposits during the year under review from the Directors and their relative, which is more particularly described in the notes of the Balance Sheet, which is out of the purview of deposit as per section 2(31) of the Companies Act, 2013 and any amendments thereto.

20. **PARTICULARS OF LOAN, GUARANTEE OR INVESTMENTS:**

There were no loans, guarantees or investments made by the Company under section 186 of the Companies Act, 2013 during the year under review.

21. **RISK MANAGEMENT POLICY:**

The Company does not have any Risk Management Policy as the elements of risk threatening the Company's existence are very minimal.

22. **DISCLOSURE ABOUT CORPORATE SOCIAL RESPONSIBILITY POLICY:**

The Company is not required to constitute a Corporate Social Responsibility Committee, as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility.

23. **CONTRACTS AND ARRANGEMENTS WITH RELATED PARTY:**

There was no contract or arrangements made with related parties as defined under Section 188(1) i.e. contract and arrangement not at arm's length price under the Companies Act, 2013 during the year under review and contracts or arrangement made with related parties at arm's length basis in the ordinary course of business enclosed in (Annexure II).

24. **DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY ANY REGULATORY AUTHORITY / TRIBUNAL/ COURT:**

During the period under review no order passed by any Regulatory Authority or Courts or tribunals impacting the going concern status and company operation in future.

25. **PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE [“POSH”]:**

The Company is committed to provide a safe and conducive work environment to all of its employees. In line with this, your Company has in place a policy for prevention of sexual harassment at workplace as per the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ('POSH') and Rules made thereunder. Further, the Policy also gives shelter to woman trainees and retainers. In line with the requirements of the said Act, an Internal Complaints Committee ('ICC') has been set up to redress the complaints received regarding sexual harassment at workplace.

Further, during the year, No. of sexual harassment complaint received - nil, No. of such complaint disposed off - nil & there are no cases pending for more than 90 days.

26. **SECRETARIAL STANDARDS:**

The Company has also complied with the provisions of secretarial standards as specified in accordance with the provisions of the Companies Act, 2013.

27. **MAINTENANCE OF COST RECORDS**

Central Government has specified the maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013 and accordingly such accounts and records are made and maintained.

28. **INTERNAL FINANCIAL CONTROL:**

The Company has Internal Financial Control System commensurate with the size and Nature of the Business more particularly described in the auditor's report.

29. **MATERNITY BENEFIT:**

During year under review, the Company has complied with the applicable provisions of the Maternity Benefit Act, 1961 related to providing maternity benefits to female employees.

30. **DETAILS OF APPLICATION MADE OR PROCEEDING PENDING UNDER INSOLVENCY AND BANKRUPTCY CODE 2016**

During the under review, there were no application made or proceeding pending in the name of the company under the Insolvency Bankruptcy Code, 2016.

31. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS

During the period under review, there has been no one time settlement of Loans taken from Banks and Financial Institutions and hence there was no need to undertake valuation also for the same.

32. ACKNOWLEDGEMENT:

The Board expresses its sincere gratitude to the shareholders, State and Central Government Officials and clients for their continued support.

By Order of the Board
For BETABIOPHARM PRIVATE LIMITED

Place: Mumbai
Date: August 14, 2025

For Betabiopharm Pvt Ltd
SONU MEENA
Director

SONU MEENA
Director
DIN- 09758971
House No. 5, Police Line,
Nehru Nagar, Huzur
(M.P.) 462016

For Betabiopharm Pvt Ltd

KUNAL SHINDE
Director

KUNAL SHINDE
Additional Director
DIN- 11192470
39 Pragti Nagar,
Rajendra Nagar,
Indore (M.P.) India 452012

Annexure I

Particulars Pursuant to Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules 2014 and forming part of the Directors' Report for the year ended 31st March, 2025.

(I) Conservation of energy-

(i) Adequate steps have been taken by the Company at every stage of production for conservation of energy.

(ii) The step taken by the Company for conservation of energy will result in reduction of energy consumption and consequent impact on the cost of production in the coming years.

(iii) The information pertaining to total energy consumption and energy consumption per unit of production.

Power & Fuel Consumption:

Particular's	(Amount in Lakhs)	
	2024-25	2023-24
Electricity		
Purchased:	N.A	N.A
Unit :		
Total Amount (Rs. in Lakhs)		
Rate / Unit Rs.		
Own Generation:		
Units generated	N.A	N.A
Per ltr of Fuel Cost		
Unit Rs.		
Coal		
Quantity MT	N.A	N.A
Total Cost (Rs. in Lakhs)		
Average Rate / MT		
Furnace Oil		
Quantity KL	N.A	N.A
Total Cost Rs. in Lakhs		
Rate / KL Rs.		
Other internal generation		
Total Cost (Rs. in Lakhs)	N.A	N.A
Rate / Unit		

(II) Technology absorption-


The Company has carried no Research and Development activities during the year under review, however the Company continues to take measures to improve the process and reduce the cost time to time when found feasible. The company has not imported any technology.

(III) Foreign Exchange earning & Outgo

The foreign exchange earnings of the Company during the year 2024-25 were Rs 0.00 (Previous year Rs 0.00). During the year the total foreign exchange outgo was Rs 0.00 (Previous year Rs 0.00)

By Order of the Board
For BETABIOPHARM PRIVATE LIMITED

Place: Mumbai
Date: August 14, 2025

For Betabiopharm Pvt Ltd

Director

SONU MEENA
Director
DIN-09758971
House No. 5, Police Line,
Nehru Nagar, Huzur
(M.P.) 462016

For Betabiopharm Pvt Ltd

Director

KUNAL SHINDE
Additional Director
DIN- 11192470
39 Pragti Nagar,
Rajendra Nagar,
Indore (M.P.) India 452012

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	NA
b)	Nature of contracts/arrangements/transaction	NA
c)	Duration of the contracts/arrangements/transaction	NA
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	NA
e)	Justification for entering into such contracts or arrangements or transactions'	NA
f)	Date of approval by the Board	NA
g)	Amount paid as advances, if any	NA
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	NA

2. Details of material contracts or arrangement or transactions at arm's length basis

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	Balaji Steroids and Hormones Pvt. Ltd. (KMP has significant influence)
b)	Nature of contracts/arrangements/transaction	Purchase & Sale

c)	Duration of the contracts/arrangements/transaction	F.Y. 2024-25
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	NA
e)	Date of approval by the Board	08/04/2024
f)	Amount paid as advances, if any	NIL

By Order of the Board
For BETABIOPHARM PRIVATE LIMITED

Place: Mumbai
Date: August 14, 2025

For Betabiopharm Pvt Ltd
Director

SONU MEENA
Director
DIN-09758971
House No. 5, Police Line,
Nehru Nagar, Huzur
(M.P.) 462016

For Betabiopharm Pvt Ltd
Director

KUNAL SHINDE
Additional Director
DIN- 11192470
39 Pragti Nagar,
Rajendra Nagar,
Indore (M.P.) India 452012



Independent Auditor's Report to the Members of Betabiopharma Private Limited

Report on the Financial Statements

Opinion

We have audited the accompanying financial statements of **Betabiopharma Private Limited** ('the Company'), which comprise the balance sheet as at 31 March 2025, the statement of profit and loss, the statement of cash flows for the year then ended and a summary of the significant accounting policies and other explanatory information (herein after referred to as "financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, the profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Other Matters

The financial statements of the Company for the year ended 31 March 2024 included in these financial statements, have been audited by the predecessor auditor who expressed an unmodified opinion on the financial statements for the year ended 31 March 2024 on 02 September 2024.

Responsibilities of Management for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.





In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore





the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of section 143(11) of the Act, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable;
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) the balance sheet, the statement of profit and loss and the statement of cash flows dealt with by this Report are in agreement with the books of account;
 - (d) in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act read with relevant rule issued thereunder;
 - (e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act; and
 - (f) reporting to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls in terms of Section 143(3)(1) of the Act, does not apply to the Company.
3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - a. The Company does not have any pending litigations which would impact its financial position.
 - b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - d. (i) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or
provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.





MITTAL AGARWAL & COMPANY
CHARTERED ACCOUNTANTS

- (ii) The management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:

directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or

provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries; and

- (iii) Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under subclause (d) (i) and (d) (ii) contain any material mis-statement.

- e. The Company has not declared or paid any dividend during the year.
- f. Based on our examination, which included test checks, the Company has not used an accounting software for maintaining its books of account for the financial year ended March 31, 2025 which has a feature of recording audit trail (edit log) facility. Further, the Company is in process to obtaining the same.
4. With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act:
In our opinion and according to the information and explanations given to us and based on examination of the records of the Company, the provision of section 197 is not applicable to the Company.

For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)



Deepesh Mittal

Deepesh Mittal
Partner
Membership No. 539486

Place: Mumbai
Dated: 14/08/2025
UDIN: 25539486BMKSMP7584



MITTAL AGARWAL & COMPANY
CHARTERED ACCOUNTANTS

Annexure A to the Independent Auditors' Report on the financial statements of Betabiopharm Private Limited for the year ended 31 March 2025

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

- 1a A. The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
 - B. The Company has maintained proper records showing full particulars of Intangible Assets.
- 1b According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- 1c The Company does not hold any Immovable Property. Accordingly, clause 3(i)(c) of the Order is not applicable to the Company.
- 1d According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment or Intangible Assets or both during the year.
- 1e According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- 2a According to information and explanations given to us and on the basis of our examination of records of the Company, the management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion the coverage and the procedure of such verification by the management is appropriate. No material discrepancies were noticed on such physical verification.
- 2b According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. Accordingly, clause 3(ii)(b) of the Order is not applicable to the Company.
- 3 According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties during the year. Accordingly, clause 3(iii) of the Order is not applicable to the Company.
- 4 According to the information and explanations given to us and on the basis of our examination of records of the Company, the Company has not made any investment and has not provided any guarantee or security as specified under Sections 185 and 186 of the Act. In respect of the loans given by the Company, in our opinion the provisions of Sections 185 and 186 of the Act have been complied with.





MITTAL AGARWAL & COMPANY
CHARTERED ACCOUNTANTS

- 5 The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable to the Company.
- 6 According to the information and explanations given to us, the Central Government has not prescribed the maintenance of cost records under Section 148(1) of the Companies Act, 2013 for the products manufactured by it (and/or services provided by it). Accordingly, clause 3(vi) of the Order is not applicable to the Company.
- 7a The Company does not have liability in respect of Sales tax, Service tax, Duty of excise and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.
- According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Goods and Services Tax ('GST'), Income-tax, Duty of Customs, Cess, Provident fund, Employees' State Insurance and other material statutory dues have generally been regularly deposited with the appropriate authorities.
- According to the information and explanations given to us, no undisputed amounts payable in respect of GST, Income-tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.
- 7b According to the information and explanations given to us, there are no material dues of income tax, sales tax, value added tax, service tax, goods and service tax, duty of customs, duty of excise which have not been deposited with the appropriate authorities on account of any dispute.
- 8 According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
- 9a According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans or borrowings or in the payment of interest to any lender during the year.
- 9b According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- 9c According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not obtained any loans during the year. Accordingly, provision of clause 3(ix)(c) of the Order is not applicable to the Company.
- 9d According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.
- 9e According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Companies Act, 2013. Accordingly, clause 3(ix)(e) of the Order is not applicable to the Company.





MITTAL AGARWAL & COMPANY
CHARTERED ACCOUNTANTS

- 9f According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries as defined under the Companies Act, 2013. Accordingly, clause 3(ix)(f) of the Order is not applicable to the Company.
- 10a The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- 10b According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable to the Company.
- 11a Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- 11b According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- 11c We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.
- 12 According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable to the Company.
- 13 In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Sections 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable Indian Accounting Standards.
- 14a In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act 2013, Accordingly, clause 3(xiv)(a) of the Order is not applicable to the Company.
- 14b In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act 2013, Accordingly, clause 3(xiv)(b) of the Order is not applicable to the Company.
- 15 In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- 16a The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable to the Company.
- 16b The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable to the Company.
- 16c The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable to the Company.





MITTAL AGARWAL & COMPANY
CHARTERED ACCOUNTANTS

- 16d According to the information and explanations provided to us during the course of audit, the Group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016) does not have any CIC.
- 17 The Company has not incurred any cash losses in the current financial year and immediately preceding financial year.
- 18 There has been resignation of the statutory auditors during the year and the outgoing auditors have not provided any issues, objections or concerns.
- 19 According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- 20 In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable to the Company.

For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)



Deepesh Mittal
ms Hal

Deepesh Mittal
Partner
Membership No. 539486

Place: Mumbai
Dated: 14/08/2025
UDIN: 25539486BMKSMP7584

**Audited Balance Sheet
and
Statement of Profit And Loss**

For the Year Ended

March 31st, 2025

Betabiopharm Private Limited

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997
Balance Sheet as at March 31st, 2025

Particulars	Note	As at March 31st, 2025	(₹ in Lakhs) As at March 31st, 2024
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	1	11.00	11.00
Reserves and Surplus	2	<u>264.59</u>	<u>0.68</u>
		275.59	11.68
Non Current Liabilities			
Long Term Borrowings	3	-	-
Current Liabilities			
Trade and Other Payables Due to Micro and Small Enterprises Other than Micro and Small Enterprises	4	1,216.22	544.84
Other Current Liabilities	5	112.88	35.62
Provisions	6	<u>223.77</u>	<u>-</u>
Total		<u>1,828.46</u>	<u>592.15</u>
ASSETS			
Non-Current Assets			
Property, Plant and Equipment Property, Plant and Equipment Intangible Assets	7	81.64	0.90
Deferred Tax Assets	8	0.34	0.34
Long Term Loans and Advances	9	0.87	0.15
Current Assets			
Inventories	10	24.70	35.58
Trade Receivables	11	1,695.84	480.24
Cash and Cash Equivalents	12	8.22	47.92
Short Term Loans and Advances	13	15.30	26.04
Other current assets	14	<u>1.55</u>	<u>0.98</u>
Total		<u>1,828.46</u>	<u>592.15</u>

See Accompanying Notes to the Financial Statements.

As per our report of even date

For **Mittal Agarwal & Company**
Chartered Accountants
Registration No. 131025W

Deepesh Mittal
Deepesh Mittal
Partner
M. No. 539486



Place: Mumbai
Date: 14/08/2025

1 to 31

For and on behalf of the Board
For Betabiopharm Pvt Ltd

Kunal Shinde
Kunal Shinde
Director
DIN: 11192470

Director

Sonu Meena
For Betabiopharm Pvt Ltd

Sonu Meena
Director
DIN: 09758971

Director

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997
Statement of Profit and Loss For the Year Ended March 31st, 2025

Particulars	Note	Year Ended	
		March 31st, 2025	March 31st, 2024
Income			
Revenue from Operations	15	3,405.73	1,288.34
Other Income	16	-	0.01
Total Income		3,405.73	1,288.35
Expenditure			
Purchase of Stock-in-Trade	17	2,770.87	1,257.22
Changes in Inventories of Finished Goods	18	10.88	(9.20)
Employee Benefits Expense	19	28.68	8.13
Finance Cost		-	-
Depreciation and Amortisation Expenses	20	0.31	0.17
Other Expenses	21	242.32	30.23
Total Expenses		3,053.06	1,286.55
Profit before tax		352.68	1.80
Tax Expenses			
Current year		88.77	-
Deferred Tax		-	(0.00)
Profit for the year		263.91	1.80
Earnings per Equity share of face value of Rs. 10 each			
Basic and Diluted	22	23.99	0.16

See Accompanying Notes to the Financial Statements. 1 to 31

As per our report of even date

For **Mittal Agarwal & Company**
Chartered Accountants
Registration No. 131025W

Deepesh Mittal
Partner
M. No. 539486



Place: Mumbai
Date: 14/08/2025

For and on behalf of the Board

For **Betabiopharm Pvt Ltd**
Director

Kunal Shinde
Director
DIN: 11192470

For **Betabiopharm Pvt Ltd**
Director

Sonu Meena
Director
DIN: 09758971

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997
Cash Flow Statement for the Year Ended March 31st, 2025

(₹ in Lakhs)

Particulars	Year Ended March 31st, 2025	Year Ended March 31st, 2024
A: Cash Flow from Operating Activities:		
Net Profit before tax as per Statement of Profit and Loss	352.68	1.80
Adjusted for:		
Profit on Sale of Assets		
Depreciation and Amortisation Expense	0.31	0.17
Income Tax Refund	-	(0.01)
	352.99	1.96
Operating Profit before Working Capital Changes		
Adjusted for:		
Trade and Other Receivables	(1,215.60)	(447.94)
Inventories	10.88	(9.20)
Other Current Assets	(0.57)	3.61
Short Term Loans and Advances	10.74	(16.04)
Trade and Other Payables	671.38	479.99
Other Current Liabilities	77.26	35.62
Short Term Provisions	135.00	-
	(310.92)	46.05
Cash Generated from / (Used in) Operations	42.06	48.01
Taxes Paid (net)	-	-
Net Cash Flow used in Operating Activities	42.06	48.01
B: Cash Flow From Investing Activities:		
Purchase of Fixed Assets (Net)	(81.05)	(1.07)
Long Term Loans and Advances	(0.72)	-
Net Cash Flow used in Investing Activities	(81.77)	(1.07)
C: Cash Flow From Financing Activities:		
Long Term Liabilities (net)	-	-
Net Cash Generated from / (used in) Financing Activities	-	-
Net (Decrease) / Increase in Cash and Cash Equivalents	(39.71)	46.94
Opening Balance of Cash and Cash Equivalents	47.92	0.98
Closing Balance of Cash and Cash Equivalents	8.21	47.92

As per our report of even date

For **Mittal Agarwal & Company**
Chartered Accountants
Registration No. 131025W

Deepesh Mittal
Deepesh Mittal
Partner
M. No. 539486

Place: Mumbai
Date: 14/08/2025

For and on behalf of the Board

Kunal Shinde
For Betabiopharm Pvt Ltd
Director

Kunal Shinde
Director
DIN: 11192470

Sonu Meena
For Betabiopharm Pvt Ltd
Director

Sonu Meena
Director
DIN: 09758971



Summary of significant accounting policies and other explanatory information

1 General information

Betabiopharm PVT. LTD. ('the Company') was incorporated on 07 October 2022, with its registered office at FF-127, Windsor Plaza Nr. Express Hotel, Alkapuri, Vadodara, Gujarat, India - 390007.
All amounts in the financial statements are presented in Indian Rupees (₹).

2 Summary of significant accounting policies

a) Basis of preparation

The financial statements are prepared under the historic cost convention on accrual basis of accounting in accordance with generally accepted accounting principles ("GAAP") applicable in India. GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, (to the extent notified and applicable). Accounting policies have been consistently applied as in the previous year. The management evaluates all recently issued or revised accounting standards on an ongoing basis.

The Company is a Small and Medium Sized Company (SMC) as defined in the general instructions in respect of Accounting Standards notified under the Companies Act 2013. Accordingly the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.

b) Use of estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent liabilities as at the date of financial statements and the reported amounts of revenues and expenses during the year. The key estimates made by the Company in preparing these financial statements include provision for doubtful receivables, future obligations under employee retirement benefit plans, income taxes and the useful lives of property, plant and equipment and intangible assets. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from those estimates and the difference between the actual result and the estimates are recognised in the financial statements in the period in which the results are known/materialise.

Assets and liabilities are classified as current or non-current as per Company's normal operating cycle and other criteria set out in schedule III to the Act. Based on the nature of work, the Company has ascertained its operating cycle as upto twelve months for the purpose of current and non-current classification of assets and liabilities.

c) Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation/amortization and impairment losses, if any. Costs include all expenses incurred to bring the asset to its present location and condition.

Depreciation is provided under straight line method, derived based on the estimated useful life of the property, plant and equipment, as detailed below, determined by the management based on an assessment earlier carried out on the extent of usage of these assets considering the nature of business, accordingly these useful lives are lower than those prescribed by Schedule II to the Act.

Gains or losses arising on the disposal of the property, plant and equipment are determined as the difference between the disposal proceeds and the carrying amount of the assets and are recognized in the statement of profit and loss within other income or other expenses, as the case may be.

d) Intangible assets and amortization

Acquired capital software licenses are capitalized on the basis of the costs incurred to acquire and install the specific software. These assets are amortized over the estimated useful lives on straight line basis, commencing from the date the asset is available to the Company for its use.

After initial recognition, intangible assets are carried at its cost less any accumulated amortization and any accumulated impairment losses.

When an intangible asset is disposed of, the gain or loss on disposal is determined as the difference between the disposal proceeds and the carrying amount of the asset, and is recognized within the statement of profit and loss within other income or other expenses, as the case may be.

The amortization period and method are reviewed at each balance sheet date. If the expected useful life of the asset is significantly different from the previous estimates, the amortization period is changed accordingly. If there has been a significant change in the expected pattern of economic benefit from the asset, the method of amortization is changed to reflect the changed pattern. Such changes are accounted in accordance with Accounting Standard (AS) 5, Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting policies.

e) Impairment

The Company assesses at each balance sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. An asset's recoverable amount is the higher of an asset's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life.

If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the statement of profit and loss. If at the balance sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciated historical cost and is accordingly reversed in the statement of profit and loss.

f) Revenue recognition

Income from rendering of services

Revenue from providing technical documentation, engineering services, software solutions and other related services are recognized, on an accrual basis, in accordance with the terms of agreement entered into with the customer. The company collects goods and services tax on behalf of the government, and therefore it is not an economic benefit flowing to the company and is excluded from income.

Other revenues

Interest income on deposits with banks is recognized on time proportion basis taking into account the amount outstanding and the rate applicable.



For Betabiopharm Pvt Ltd
Director

For Betabiopharm Pvt Ltd
Director

l) Cash flow statement

Cash flows are reported using the indirect method, whereby profit / loss before extraordinary items and tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, financing and investing activities of the Company are segregated based on the available information. Cash and Cash equivalents for the purpose of cash flow statement comprise cash at bank and in hand, including cheques in hand and short-term investments with an original maturity of three months or less.

m) Provisions, contingent liabilities and contingent assets

The Company creates a provision when there is present obligation as a result of past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are neither recognized nor disclosed in the financial statements.

n) The company does not have any relationship with any companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.


o) The Company does not have any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period.


p) No Scheme of Arrangements have been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.

q) The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other source or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall: (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries. Similarly, the company has not received any funds from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall: (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

r) Steps have been taken to identify the suppliers who qualify under the definition of macro and small enterprises, as defined under the Macro, Small & Medium Enterprises Development Act 2006 despite best efforts. Since no intimation has been received from the suppliers regarding their status under the act as at 31st March 2025, disclosures relating to amounts unpaid as at the year end, if any, have not been furnished. In the opinion of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the act, is not expected to be material.



For Betabiopharm Pvt Ltd

Director

For Betabiopharm Pvt Ltd

Director

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	As at March 31st, 2025	As at March 31st, 2024
1. Share Capital		
Authorised Share Capital:		
1,10,000 (Previous Year: 1,10,000) Equity Shares of ₹ 10 each	11.00	11.00
Issued, Subscribed and Fully Paid up:		
1,10,000 (Previous Year: 1,10,000) Equity Shares of ₹ 10 each	11.00	11.00
Total	11.00	11.00
1.1 The reconciliation of the number of shares outstanding is set out below:		
Particulars	March 31st, 2025	March 31st, 2024
	No. of Shares	No. of Shares
Equity Shares at the beginning of the year	1,10,000	1,10,000
Add: Shares issued during the year	-	-
Equity shares at the end of the year	1,10,000	1,10,000
1.2 The details of Shareholders holding more than 5% shares:		
Name of the Shareholder	March 31st, 2025	March 31st, 2024
	No. of Shares	No. of Shares
	% held	% held
Dewaste Environment Solutions Private Limited	1,07,800	-
	98.00%	0.00%
Jasmina Prem Aildasani	-	1,04,500
	0.00%	95.00%
1.4 Shares Held by Promoters and Promoter Group at the End of the Year:		
Name of the Promoters	March 31st, 2025	March 31st, 2024
	No. of Shares	No. of Shares
	% held	% held
	% Change	% Change
Dewaste Environment Solutions Private Limited	1,07,800	-
	98.00%	0.00%
	98.00%	0.00%
Jasmina Prem Aildasani	-	1,04,500.00
	0.00%	95.00%
	-95.00%	0.00%
Sonu Meena	2,200.00	2,200.00
	2.00%	2.00%
	0.00%	0.00%
Chiragkumar Bipinbhai Shah	-	3,300.00
	0.00%	3.00%
	-3.00%	0.00%
2. Reserve and Surplus		
Surplus / (Deficit) in the Statement of Profit and Loss		
As per last Balance Sheet	0.68	(1.12)
Add: Profit / (Loss) for the year	263.91	1.80
Total	264.59	0.68



For Betabiopharm Pvt Ltd

[Signature]
Director

For Betabiopharm Pvt Ltd

[Signature]
Director

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	As at March 31st, 2025	As at March 31st, 2024
3. Long Term Borrowings		
Unsecured		
From Related Parties (Refer Note 24)	-	-
Total	<u>-</u>	<u>-</u>
4. Trade Payables		
(Unsecured and Considered good)		
Due to Micro and Small Enterprises	-	-
Other than Micro and Small Enterprises (Refer Note 24)	1,216.22	544.84
Total	<u>1,216.22</u>	<u>544.84</u>

4.1 Pursuant to disclosure of amount due to Micro, Small and Medium Enterprises as defined under the "Micro, Small and Medium Enterprises Development Act, 2006" (MSMED ACT) included under the head "Trade Payable", the Company has initiated process of seeking necessary information from its suppliers based on the information available with the company regarding the total amount due to supplier as covered under MSMED Act is given below. The company is generally regular in making payment of dues to such enterprise. This has been relied upon by the auditors.

Particulars

i. The principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year		
a. Principal amount due to micro and small enterprises	-	-
b. Interest due on above	-	-
ii. The amount of interest paid by the buyer in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 along with the amount of the payment made to the supplier beyond the appointed day during each accounting year	-	-
iii. The amount of interest due and payable for the period of delay in making payment but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006	-	-
iv. The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
v. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under Section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-

Note : The above information has been compiled in respect of parties to the extent to which they could identify as Micro and small enterprises on the basis of information available with the Company.



for Betabiopharm Pvt Ltd
[Signature]
Director

for Betabiopharm Pvt Ltd
[Signature]
Director

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	As at March 31st, 2025	As at March 31st, 2024
4.3 Ageing of Trade Payables		
Micro Enterprises and Small Enterprises		
Less than 1 Year	-	-
1 Year - 2 Years	-	-
2 Years - 3 Years	-	-
More than 3 Years	-	-
Other than Micro Enterprises and Small Enterprises		
Less than 1 Year	1,214.22	544.84
1 Year - 2 Years	2.00	-
2 Years - 3 Years	-	-
More than 3 Years	-	-
Micro Enterprises and Small Enterprises - Disputed Dues		
Less than 1 Year	-	-
1 Year - 2 Years	-	-
2 Years - 3 Years	-	-
More than 3 Years	-	-
Other than Micro Enterprises and Small Enterprises - Disputed Dues		
Less than 1 Year	-	-
1 Year - 2 Years	-	-
2 Years - 3 Years	-	-
More than 3 Years	-	-
	<u>1,216.22</u>	<u>544.84</u>
5. Other Current Liabilities		
Statutory Dues	87.78	0.21
Income received in advance	-	35.16
Salary Payable	20.00	-
Audit Fees Payable	1.75	0.25
Advances from Customers	3.35	-
Total	<u>112.88</u>	<u>35.62</u>
6. Provisions		
Provision for Income tax	88.77	-
Return Material Recovery From Party	135.00	-
Total	<u>223.77</u>	<u>-</u>



For Betabiopharm Pvt Ltd
[Signature]
Director

For Betabiopharm Pvt Ltd
[Signature]
Director

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	As at March 31st, 2025	As at March 31st, 2024
8. Deferred Tax Assets		
Opening Balance	0.34	0.33
Related to Fixed Assets	-	0.00
Total	0.34	0.34
9. Long Term Loans and Advances (Unsecured and Considered good)		
Security Deposits	0.87	0.15
Total	0.87	0.15
10. Inventories		
Finished Goods	24.70	35.58
Total	24.70	35.58
10.1 Valuation of Inventories are as Valued and Certified by the Management.		
11. Trade Receivables (Unsecured and Considered good)		
Debts outstanding for a period exceeding 6 months	-	-
Other debts	1,695.84	480.24
Total	1,695.84	480.24

Age of Receivable

Undisputed Trade Receivables – Considered Good

Less than 6 months	1,533.93	480.24
6 Months - 1 Year	24.47	-
1 Year - 2 Years	137.44	-
2 Years - 3 Years	-	-
More than 3 Years	-	-

Undisputed Trade Receivables – Considered Doubtful

Less than 6 months	-	-
6 Months - 1 Year	-	-
1 Year - 2 Years	-	-
2 Years - 3 Years	-	-
More than 3 Years	-	-

Disputed Trade Receivables Considered Good

Less than 6 months	-	-
6 Months - 1 Year	-	-
1 Year - 2 Years	-	-
2 Years - 3 Years	-	-
More than 3 Years	-	-

Disputed Trade Receivables Considered Doubtful

Less than 6 months	-	-
6 Months - 1 Year	-	-
1 Year - 2 Years	-	-
2 Years - 3 Years	-	-
More than 3 Years	-	-
Total	1,695.84	480.24



For Betabiopharm Pvt Ltd
[Signature]
Director

For Betabiopharm, Pvt Ltd
[Signature]
Director

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	As at March 31st, 2025	As at March 31st, 2024
12. Cash and Cash Equivalents		
Cash on Hand	0.91	0.91
Balances with Banks		
In Current Accounts	7.30	47.01
Total	8.22	47.92
13. Short Term Loans and Advances		
Loans and advances to related parties (Refer Note 24)		
(i) Secured, considered good;	-	-
(ii) Unsecured, considered good	-	25.72
(iii) Doubtful.	-	-
Other loans and advances		
(i) Secured, considered good;	-	-
(ii) Unsecured, considered good;	15.30	0.33
(iii) Doubtful.	-	-
Total	15.30	26.04
14. Other Current Assets		
Balance with		
Direct Tax Authorities	1.55	0.48
Indirect tax Authorities	-	0.50
	1.55	0.98



For Betabiopharm Pvt Ltd
[Signature]
Director

For Betabiopharm Pvt Ltd
[Signature]
Director

Betabiopharm Private Limited
CIN: U51909GJ2022PTC135997

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

7. Property, Plant and Equipment

Particulars	Gross Block				Depreciation / Amortisation				Net Block	
	As on 01.04.2024	Additions	Deductions / Adjustments	As on 31.03.2025	Upto 01.04.2024	For the Year	Deductions / Adjustments	Upto 31.03.2025	As on 31.03.2025	As on 31.03.2024
Property, Plant and Equipment										
Office Other Items	-	0.12	-	0.12	-	0.02	-	0.02	0.10	-
Furniture and Fixtures	-	80.23	-	80.23	-	-	-	-	80.23	-
Active	-	0.70	-	0.70	-	0.05	-	0.05	0.65	-
Mobile	0.90	-	-	0.90	-	0.23	-	0.23	0.67	0.90
Sub-Total	0.90	81.05	-	81.95	-	0.31	-	0.31	81.64	0.90
Previous Year	-	1.07	-	1.07	-	0.17	-	0.17		0.90



For Betabiopharm Pvt Ltd
[Signature]
Director

For Betabiopharm Pvt Ltd
[Signature]
Director

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	Year Ended March 31st, 2025	Year Ended March 31st, 2024
15. Revenue From Operations		
Sale of Products (Refer Note 24)	3,405.73	1,288.34
Total	3,405.73	1,288.34
16. Other Income		
Income Tax Refund	-	0.01
Total	-	0.01
17. Purchase of Stock-in-Trade		
Purchase of Stock-in-Trade (Refer Note 24)	2,770.87	1,257.22
Total	2,770.87	1,257.22
18. Changes in Inventories of Finished Goods, Stock-in-Process and Scrap		
Inventories (at close)		
Finished Goods	24.70	35.58
	24.70	35.58
Inventories (at commencement)		
Finished Goods	35.58	26.38
	35.58	26.38
	10.88	(9.20)
19. Employee Benefits Expense		
Salaries and Wages	28.68	8.13
Total	28.68	8.13
20. Depreciation and Amortisation Expense		
Depreciation and Amortisation Expenses	0.31	0.17
Total	0.31	0.17



For Betabiopharm Pvt Ltd
Director

For Betabiopharm Pvt Ltd
Director

Betabiopharm Private Limited


CIN: U51909GJ2022PTC135997

Notes on Financial Statements For the Year Ended March 31st, 2025

(₹ in Lakhs)

	Year Ended March 31st, 2025	Year Ended March 31st, 2024
21. Other Expenses		
Audit Fees	1.75	0.25
Advertisement & Publicity	-	1.00
Bank Charges	0.80	0.05
Business Prmotion Exp- Dubai	-	1.42
Business Promotion Ecp	55.25	9.21
Discount Given	0.80	1.25
Electricity Exp	0.08	0.24
Freight & Cratage	3.19	0.04
Insurance Expenses	0.00	0.00
Legal & Professional Fees	1.49	1.44
Medical Expenses	-	2.62
Office Expenses	22.07	4.01
POSTAGE & COURIER	0.14	0.04
Rent Expenses	4.68	1.80
Office Renovation Exp	0.27	2.58
Tax Expenses	0.26	-
Commission & Brokrage Expenses	6.55	4.27
Job Work Expenses (Refer Note 24)	145.00	-
Total	242.32	30.23
21.1 Payment to Auditor as:		
Statutory Audit Fees	1.75	0.25
Tax Audit Fees	-	-
	1.75	0.25
22. Earning Per Share (EPS)		
i) Net Profit after tax as per Statement of Profit and Loss attributable Equity Share holders (Rs.)	263.91	1.80
ii) Weighted Average number of Equity Shares used as denominator for calculating EPS	11.00	11.00
iii) Basic and Diluted Earnings per share (Rs.)	23.99	0.16
iv) Face Value per Equity Share (Rs.)		
23. Contingent Liabilities and Commitments		
(I) Contingent Liabilities (to the extent not provided for)		
a Bank Guarantees opened with banks	-	-
b Custom Duty payable against Export Obligation	-	-
(II) Commitments		
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)	-	-



For Betabiopharm Pvt Ltd

 Director

For Betabiopharm Pvt Ltd

 Director

Notes on Financial Statements For the Year Ended March 31st, 2025

24. Related Party Disclosures

As per Accounting Standard 18, the disclosures of transactions with the related parties are given below:

- i) List of related parties where control exists and related parties with whom transactions have taken place and relationships:

Sr. No.	Name of the Related Party	Relationship
1.	Sonu Meena	Key Managerial Personnel (KMP)
2.	Jasmina Aildasani (resigned on 10/07/2025)	
3.	Kunal Shinde (appointed on 10/07/2025)	
6.	Balaji Steroids & Hormones Private Limited	Enterprises over which KMP are able to exercise influential control

- ii) Transactions during the year with related parties:

Sr. No.	Nature of Transactions	₹ in Lakhs	
		Year ended March 31st, 2025	Year ended March 31st, 2024
1	Advances for Expenses / Capital Expenditure Key Managerial Personnel (KMP) Jasmina Aildasani	-	25.72
2	Purchase of Fixed Assets Key Managerial Personnel (KMP) Jasmina Aildasani	80.23	-
3	Sales of goods Enterprises over which KMP are able to exercise influential control Balaji Steroids & Hormones Private Limited	1,932.12	121.49
4	Purchases Enterprises over which KMP are able to exercise influential control Balaji Steroids & Hormones Private Limited	866.52	1,028.76
5	Job work Expenses Enterprises over which KMP are able to exercise influential control Balaji Steroids & Hormones Private Limited	145.00	-

Closing Balances as at

	Closing Balance	As at March 31st, 2025	As at March 31st, 2024
6	Advances for Expenses / Capital Expenditure Key Managerial Personnel (KMP) Jasmina Aildasani	43.35	25.72
7	Trade Payable Enterprises over which KMP are able to exercise influential control Balaji Steroids & Hormones Private Limited	1,389.84	501.93

25. Segment Information

Disclosure under AS 17 -The Company has only a single reportable Segment in terms of the requirements of AS-17. There is no customer having revenues exceeding 10% of total Revenues



For Betabiopharm Pvt Ltd
[Signature]
Director

For Betabiopharm Pvt Ltd
[Signature]
Director

Notes on Financial Statements For the Year Ended March 31st, 2025

26. Ratios

	<u>As at March 31st, 2025</u>	<u>As at March 31st, 2024</u>	<u>Changes</u>	<u>Reason</u>
(i) Current Ratio (Total current assets/Total current liabilities)	1.12	1.02	10.45%	Due to increase in short term loans and advances
(ii) Debt-Equity Ratio (Total Debt/Total Equity)	-	-	NA	Due to increase in Reserves and surplus
(iii) Debt Service Coverage Ratio (Profit Before Interest & Tax/Debt Service)	NA	NA	NA	
(iv) Inventory Turnover Ratio (Sale of Products (Refer Note 24)/Average Inventory)	113.01	41.59	171.71%	Due to increase in revenue from operations
(v) Trade Receivables Turnover Ratio (Revenue from Operation/Average Trade Receivable)	3.13	5.03	-37.74%	Due to increase in revenue from operations
(vi) Trade Payables Turnover Ratio (Net Credit Purchases (Raw Material, Packing Material and Purchase of Traded Goods) / Average Trade Payable)	3.87	4.23	-8.48%	
(vii) Net Capital Turnover Ratio (Revenue from Operations/Working Capital (Total Current Assets less Total Current Liabilities))	33.55	130.86	-74.36%	Due to increase in revenue from operations
(viii) Return on Equity (Profit for the Year/Total Equity)	95.76%	15.43%	520.81%	Due to increase in revenue from operations
(ix) Net Profit Ratio (Profit for the Year/Revenue from Operations)	7.75%	0.14%	5442.73%	Due to increase in revenue from operations
(x) Return on Capital Employed (Profit before Tax and Finance Costs/Capital Employed (Net worth + Lease liability + Deferred tax Liability))	127.97%	15.43%	729.63%	Due to increase in revenue from operations
(xi) Return on Investment (Income Generated from Invested funds/Average Invested Funds)	NA	NA	NA	

27. Disclosure of Transactions With Struck Off Companies

The Company did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.



For Betabiopharm Pvt Ltd

[Signature]
Director

For Betabiopharm Pvt Ltd

[Signature]
Director

Notes on Financial Statements For the Year Ended March 31st, 2025

28. No transactions to report against the following disclosure requirements as notified by MCA pursuant to amended Schedule III:

- i Crypto Currency or Virtual Currency
- ii Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder
- iii Registration of charges or satisfaction with Registrar of Companies
- iv Relating to borrowed funds:
 - a) Wilful defaulter
 - b) Utilisation of borrowed funds & share premium
 - c) Borrowings obtained on the basis of security of current assets
 - d) Discrepancy in utilisation of borrowings
 - e) Current maturity of long term borrowings

29. Debit and Credit balances are subject to confirmation and reconciliation if any.

30. With effect from April 1, 2023, the Ministry of Corporate Affairs (MCA) has made it mandatory for every company, which uses accounting software for maintaining its books of account, to use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

The Company does not use accounting software which have audit trail log further the Company is in process to obtain accounting software which have the feature of audit trail log during the FY 2025-2026.

31. Previous year figures have been regrouped / reclassified, wherever necessary, to correspond with current year classification.

For Mittal Agarwal & Company
Chartered Accountants
Registration No. 131025W

Deepesh Mittal
Deepesh Mittal
Partner
M. No. 539486



Place: Mumbai
Date: 14/08/2025

For and on behalf of the Board


For Betabiopharm Pvt Ltd



Director

Kunal Shinde
Director
DIN: 11192470

For Betabiopharm Pvt Ltd



Director

Sonu Meena
Director
DIN: 09758971